泰林生物(300813) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 was ¥60,631,217.05, a decrease of 31.11% compared to the same period last year[4] - The net profit attributable to shareholders was a loss of ¥1,882,070.90, representing a decline of 111.79% year-on-year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥3,356,942.37, down 122.26% from the previous year[4] - Total operating revenue for Q3 2023 was CNY 203,117,602.42, a decrease of 12.5% compared to CNY 233,715,392.31 in Q3 2022[21] - Operating profit for Q3 2023 was CNY 22,693,621.90, down 54.2% from CNY 49,508,058.40 in the same period last year[22] - Net profit attributable to shareholders for Q3 2023 was CNY 21,311,951.81, a decline of 55.0% compared to CNY 47,259,994.38 in Q3 2022[23] - The total comprehensive income for Q3 2023 was CNY 20,765,694.34, significantly lower than CNY 47,259,994.38 in Q3 2022[23] - The basic earnings per share for the period was -¥0.01, a decrease of 105.26% year-on-year[4] - The company reported a basic earnings per share of CNY 0.20, down from CNY 0.57 in the same quarter last year[23] Assets and Liabilities - The total assets at the end of the reporting period were ¥973,481,535.45, an increase of 5.51% compared to the end of the previous year[4] - As of September 30, 2023, total assets reached CNY 973,481,535.45, an increase from CNY 922,660,005.83 at the beginning of the year, reflecting a growth of approximately 5.7%[17] - Current assets totaled CNY 792,012,879.29, up from CNY 763,540,897.13, indicating an increase of about 3.3%[18] - The total liabilities amounted to CNY 792,012,879.29, reflecting a stable financial position[18] - Total liabilities increased to CNY 307,959,423.33, compared to CNY 275,205,185.78 in the previous year, reflecting a growth of 11.9%[22] - The total equity attributable to shareholders rose to CNY 663,368,369.59, up from CNY 647,454,820.05, marking an increase of 2.4%[22] Cash Flow - The company reported a cash flow from operating activities net amount of -¥12,510,682.38, a decline of 141.66% year-to-date[4] - Cash inflow from operating activities was CNY 247,875,761.11, down from CNY 273,407,071.87 in Q3 2022[24] - The net cash flow from operating activities was -12,510,682.38 CNY, a significant decrease compared to 30,028,000.91 CNY in the previous year[25] - Total cash outflow from investing activities was 143,711,828.05 CNY, down from 357,491,265.49 CNY year-over-year[25] - The net cash flow from financing activities was 18,243,451.57 CNY, a decrease from 235,908,125.52 CNY in the same period last year[25] - The company experienced a net decrease in cash and cash equivalents of -16,747,871.12 CNY, contrasting with an increase of 58,495,155.48 CNY in the previous year[25] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 12,402[11] - The top shareholder, Ye Daling, holds 53.21% of the shares, totaling 57,824,000 shares[11] - The total number of restricted shares decreased from 44,480,000.00 to 43,368,000.00 for Ye Daling due to the release of some shares[14] - The company plans to unlock restricted shares for key executives on January 1, 2024, including 11,120,000 shares for Ye Daling[14] Government Subsidies and Expenses - The company received government subsidies amounting to ¥1,991,146.81 during the reporting period, down from ¥4,854,991.26 year-to-date[7] - The company’s long-term deferred expenses increased by 143.18% to ¥31,538,384.66 due to rising renovation costs[9] - Research and development expenses increased to CNY 48,129,064.41, up 6.0% from CNY 45,043,262.12 in the previous year[22] - The company paid 102,189,693.30 CNY to employees, an increase from 100,461,930.25 CNY year-over-year[25] Audit Information - The company did not undergo an audit for the third quarter report[27] Market Strategy - The company is focused on expanding its market presence and enhancing its product offerings through ongoing research and development initiatives[15]